ALDXAldeyra Therapeutics, Inc.同业对比
Aldeyra Therapeutics, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALDX本股 | $84M#8 | — | 2.2x#4 | — | — | 39.4%#5 | — | -89.3%#7 | — | — | -71.9%#4 | — |
| CPIX | $104M#1 | — | 6.0x#6 | 2.3x#1 | 17.6%#2 | 56.2%#4 | -6.3%#2 | -16.3%#3 | — | — | — | — |
| PLYX | $101M#2 | — | 9.3x#8 | — | — | 70.4%#3 | — | -82.1%#6 | — | — | — | — |
| RLYB | $89M#4 | 3.4x#2 | 0.9x#2 | 104.0x#3 | 34.9%#1 | 84.5%#1 | -3853.6%#4 | -9.5%#2 | — | — | — | — |
| CTOR | $89M#5 | — | 2.2x#3 | — | — | -17.1%#11 | — | -61.3%#4 | — | — | -48.3%#3 | — |
| ANIX | $91M#3 | — | 6.3x#7 | 431.2x#4 | 0.0%#4 | 13.0%#7 | -5571.9%#5 | -75.5%#5 | -87.0%#1 | — | -27.2%#1 | — |
| EMMA | $84M#6 | — | — | 6.8x#2 | -25.2%#5 | -16.1%#10 | 1.9%#1 | — | — | 4#1 | — | — |
| MAIA | $84M#7 | — | 4.1x#5 | — | — | 3.7%#8 | — | -108.3%#9 | — | — | — | — |
| ACET | $84M#9 | — | 0.7x#1 | — | — | 0.3%#9 | — | -97.2%#8 | — | — | — | — |
| FBIO | — | 0.9x#1 | — | — | 9.7%#3 | 76.2%#2 | -111.0%#3 | 22.5%#1 | — | — | -27.9%#2 | — |
| OSTX | $80M#10 | — | — | — | — | -223.7%#12 | — | — | — | — | — | — |
| TELO | $80M#11 | — | 15.8x#9 | — | — | 37.0%#6 | — | -206.9%#10 | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议